Nutex Health reported a significant earnings beat for the second quarter of 2026, driven by operational efficiencies and a substantial reduction in arbitration-related expenses. While total revenue declined 13.6% year-over-year to $210.8 million due to high year-ago comparisons from the independent dispute resolution (IDR) process, the company achieved a major swing to profitability with net income of $65.8 million compared to a net loss in the prior year period.
Key Highlights
- Total hospital division patient visits increased 9.6% year-over-year to 49,962, exceeding analyst expectations for market capture.
- Operating expenses were significantly reduced by a $52.3 million favorable adjustment to contract services, resulting from a retroactive amendment with HaloMD and lower CMS administrative fees.
- Adjusted EBITDA attributable to the company rose to $90.0 million, up from $71.6 million in the second quarter of 2025.
- The company maintained a strong liquidity position with $205.2 million in cash and cash equivalents against just $31.1 million in long-term debt.